Apolipoprotein D (ApoD) is a protein that in humans is encoded by the APODgene.[5][6][7] Unlike other lipoproteins, which are mainly produced in the liver, apolipoprotein D is mainly produced in the brain and testes.[8] It is a 29 kDa glycoprotein discovered in 1963 as a component of the high-density lipoprotein (HDL) fraction of human plasma.[9][10] It is the major component of human mammary cyst fluid. The human gene encoding it was cloned in 1986 and the deduced protein sequence revealed that ApoD is a member of the lipocalin family, small hydrophobic molecule transporters.[6] ApoD is 169 amino acids long, including a secretion peptide signal of 20 amino acids. It contains two glycosylation sites (aspargines 45 and 78) and the molecular weight of the mature protein varies from 20 to 32 kDa (see figure 1).
Rassart Figure 1
The resolved tertiary structure shows that ApoD is composed of 8 anti-parallel β-strands forming a hydrophobic cavity capable of receiving different ligands.[11][12] ApoD also contains 5 cysteine residues, 4 of which are involved in intra-molecular disulfide bonds.
Function
Apolipoprotein D (ApoD) is a component of HDL that has no marked similarity to other apolipoprotein sequences. It has a high degree of homology to plasma retinol-binding protein and other members of the alpha 2 microglobulin protein superfamily of carrier proteins, also known as lipocalins. It is a glycoprotein of estimated molecular weight 33 KDa. Apo-D is closely associated with the enzyme lecithin-cholesterol acyltransferase (LCAT) - an enzyme involved in lipoprotein metabolism.[7] ApoD has also been shown to be an important link in the transient interaction between HDL and low-density lipoprotein (LDL) particles and between HDL particles and cells.[13]
Interactions and ligands
ApoD was shown to bind steroid hormones such as progesterone and pregnenolone with a relatively strong affinity, and to estrogens with a weaker affinity.[14][15] Molecular modeling studies identified bilirubin, a breakdown product of heme, as a potential ligand.[11]Arachidonic acid (AA) was identified as an ApoD ligand with a much better affinity than that of progesterone or pregnenolone.[16] AA is the precursor of prostaglandins and leukotrienes, molecules that are involved in inflammation, platelet aggregation and cellular regulation.[17] A very poor binding between ApoD and cholesterol has also been observed.[18]
Other ApoD ligands include E-3-methyl-2-hexenoic acid, a scent molecule present in body odor secretions;[19]retinoic acid, which is involved in cellular differentiation; and sphingomyelin and sphingolipids, which are major components of HDL and cell membranes.[20] The fact that apoD may bind such a large variety of ligands strongly support the hypothesis that it could be a multi-ligand, multi-functional protein.
Analysis of the ApoD gene promoter region identified a large number of promoterregulatory elements, among which are response elements to steroids (such as estrogen and progesterone) and glucocorticoids. Response elements to fatty acids, acute phase proteins, serum, and to the immune factor NF-κB were also observed.[22][23][24] The presence of such a large number of regulatory sequences suggests that the regulation of its expression is very complex.
ApoD has been identified in 6 mammalian species as well as in chickens,[25][26] fruit flies,[27] plants[28] and bacteria.[29] In humans, monkeys, rabbits and guinea pigs, ApoD is highly expressed in the nervous system (brain, cerebellum, and peripheral nerves). Otherwise, expression levels of ApoD vary largely from organ to organ and species to species, with humans displaying the most diverse expression of ApoD, and mice and rats almost exclusively expressing ApoD in the nervous system (see Figure 2).
Rassart Figure 2
ApoD concentration in human plasma varies between 5 and 23 mg/100 ml.[30] In the nervous system, the ApoD mRNA is expressed by fibroblasts, astrocytes and oligodendrocytes[31][32][33] As a glycoprotein with a peptide signal, ApoD is secreted. Yet it can also be actively reinternalized. The transmembrane glycoproteinBasigin (BSG; CD147) was identified as an ApoD receptor.[34] BSG is a membrane glycoprotein receptor, a member of the immunoglobulin family, involved in several pathologies such as cancer and Alzheimer's disease.[35]
Modulation of ApoD expression
Studies on several cell types have shown that ApoD expression can be induced by several stressing situations such as growth arrest, senescence, oxidative and inflammatory stresses.[23][24] ApoD expression is also increased in several neuropathologies.
ApoD expression is modulated in several pathologies such as HDL familial deficiency, Tangier disease,[36][37] LCAT familial deficit[38] and type 2 diabetes.[39] It is overexpressed in numerous cancers,[40] including breast,[41][42] ovary, prostate,[43] skin[44][45] and central nervous system (CNS) cancer. In many cases, its expression is correlated with highly differentiated, non-invasive and non-metastatic state.
A role in lipid metabolism has been identified for ApoD by a study on transgenic (Tg) mice overexpressing human ApoD in the CNS.[46] These mice slowly develop a hepatic and muscular steatosis accompanied with insulin resistance. However, none of the Tg mice develop obesity nor diabetes. ApoD induced lipid accumulation is not due to de novo lipogenesis but rather from increased lipid uptake in response to prostaglandin overproduction.[47]
Plasma ApoD levels decrease significantly during normal uncomplicated pregnancy. ApoD is further decreased in women with excessive gestational weight gain and their newborns. In these women, the ApoD concentration was tightly associated with the lipid parameters.[48] In morbidly obese women (BMI over 40) adipose tissues, ApoD protein expression is positively correlated with parameters of metabolic health.
ApoD-null female mice (mice in which the ApoD gene was inactivated) present progressive (up to 50%) bone volume reduction with aging.[49]
ApoD and the nervous system
Both ApoD and Apolipoprotein E (ApoE) protein levels increase drastically at the site of regeneration following a nerve crush injury in the rat.[50][51] Similar observations have been made in rabbits, marmoset monkeys and in mice.[52] Elevated levels of ApoD were observed in the cerebrospinal fluid, hippocampus and cortex of human patients with Alzheimer's disease, cerebrovascular disease, motoneuron disease, meningoencephalitis and stroke.[53] ApoD expression is altered in plasma and post-mortem brains of patients with schizophrenia.[54] In patients with Parkinson's disease or with multiple sclerosis, ApoD expression is strongly increased in glial cells of the substantia nigra.[55][56]
Niemann-Pick type C (NPC) is a genetic disorder affecting cholesterol transport that is accompanied by chronic progressive neurodegeneration. In animal models of NPC, ApoD expression is increased in the plasma and the brain.[57] In rats, ApoD expression increases in the hippocampus after enthorinal cortex lesioning. ApoD mRNA and protein increases in the ipsilateral region of hippocampus as early as 2 days post-lesion (DPL), remains high for 10 days and returns to normal after 14 DPL, a period considered necessary for a complete reinervation.[58] Similar results are obtained after injection of kainic acid, an analog of glutamic acid which causes a severe neurodegenerative injury in the hippocampus[59] or after experimentally-induced stoke.[60][61] ApoD expression is also increased in the aging brain.[53] Altogether, these data suggest that ApoD plays an important role in neural preservation and protection.
Tg mice are less sensitive to oxidative stress induced by paraquat, a free oxygen radical generator, and present reduced lipid peroxidation levels. In contrast, apoD-null mice show increased sensitivity to oxidative stress, increased brain lipid peroxidation and impaired locomotor and learning abilities. Similar results have been observed in a drosophila model.[62] Mice infected with the human coronavirus OC43 develop encephalitis and inflammatory demyelination of the CNS, a disease very similar to multiple sclerosis. Tg mice infected with OC43 display increased survivability compared to control animals.[63] Tg mice treated with kainic acid show a significant reduction of inflammatory responses and a much stronger protection against apoptosis in the hippocampus than control animals.[64] ApoD-null mice crossed with APP-PS1 mice, a mouse model of Alzheimer's disease, displayed a 2-fold increase of hippocampal amyloid plaque load. In contrast, the progeny of Tg mice crossed with APP-PS1 mice displayed reduced hippocampal plaque load by 35%, and a 35% to 65% reduction of amyloid peptide levels.[65]
^Ayrault Jarrier M, Levy G, Polonovski J (August 1963). "[Study of Human Serum Alpha-Lipoproteins by Immunoelectrophoresis]". Bulletin de la Société de Chimie Biologique. 45: 703–13. PMID14051455.
^McConathy WJ, Alaupovic P (February 1976). "Studies on the isolation and partial characterization of apolipoprotein D and lipoprotein D of human plasma". Biochemistry. 15 (3): 515–20. doi:10.1021/bi00648a010. PMID56198.
^ abPeitsch MC, Boguski MS (February 1990). "Is apolipoprotein D a mammalian bilin-binding protein?". The New Biologist. 2 (2): 197–206. PMID2083249.
^Breustedt DA, Schönfeld DL, Skerra A (February 2006). "Comparative ligand-binding analysis of ten human lipocalins". Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1764 (2): 161–73. doi:10.1016/j.bbapap.2005.12.006. PMID16461020.
^Lambert J, Provost PR, Marcel YL, Rassart E (20 February 1993). "Structure of the human apolipoprotein D gene promoter region". Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1172 (1–2): 190–2. doi:10.1016/0167-4781(93)90292-l. PMID7916629.
^Albers JJ, Adolphson J, Chen CH, Murayama N, Honma S, Akanuma Y (9 July 1985). "Defective enzyme causes lecithin-cholesterol acyltransferase deficiency in a Japanese kindred". Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 835 (2): 253–7. doi:10.1016/0005-2760(85)90280-2. PMID4005283.
^Baker WA, Hitman GA, Hawrami K, McCarthy MI, Riikonen A, Tuomilehto-Wolf E, et al. (December 1994). "Apolipoprotein D gene polymorphism: a new genetic marker for type 2 diabetic subjects in Nauru and south India". Diabetic Medicine. 11 (10): 947–52. doi:10.1111/j.1464-5491.1994.tb00252.x. PMID7895459. S2CID24833816.
^Ryu B, Jones J, Hollingsworth MA, Hruban RH, Kern SE (1 March 2001). "Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers". Cancer Research. 61 (5): 1833–8. PMID11280733.
^Aspinall JO, Bentel JM, Horsfall DJ, Haagensen DE, Marshall VR, Tilley WD (August 1995). "Differential expression of apolipoprotein-D and prostate specific antigen in benign and malignant prostate tissues". The Journal of Urology. 154 (2 Pt 1): 622–8. doi:10.1097/00005392-199508000-00082. PMID7541868.
^Miranda E, Vizoso F, Martín A, Quintela I, Corte MD, Seguí ME, et al. (June 2003). "Apolipoprotein D expression in cutaneous malignant melanoma". Journal of Surgical Oncology. 83 (2): 99–105. doi:10.1002/jso.10245. PMID12772203. S2CID25700567.
^West RB, Harvell J, Linn SC, Liu CL, Prapong W, Hernandez-Boussard T, et al. (August 2004). "Apo D in soft tissue tumors: a novel marker for dermatofibrosarcoma protuberans". The American Journal of Surgical Pathology. 28 (8): 1063–9. doi:10.1097/01.pas.0000126857.86186.4c. PMID15252314. S2CID5773777.
^Do Carmo S, Fournier D, Mounier C, Rassart E (April 2009). "Human apolipoprotein D overexpression in transgenic mice induces insulin resistance and alters lipid metabolism". American Journal of Physiology. Endocrinology and Metabolism. 296 (4): E802-11. doi:10.1152/ajpendo.90725.2008. PMID19176353.
^Reindl M, Knipping G, Wicher I, Dilitz E, Egg R, Deisenhammer F, et al. (1 October 2001). "Increased intrathecal production of apolipoprotein D in multiple sclerosis". Journal of Neuroimmunology. 119 (2): 327–32. doi:10.1016/s0165-5728(01)00378-2. PMID11585636. S2CID24583456.
^Ordoñez C, Navarro A, Perez C, Astudillo A, Martínez E, Tolivia J (April 2006). "Apolipoprotein D expression in substantia nigra of Parkinson disease". Histology and Histopathology. 21 (4): 361–6. doi:10.14670/HH-21.361. PMID16437381.
^Yoshida K, Cleaveland ES, Nagle JW, French S, Yaswen L, Ohshima T, et al. (October 1996). "Molecular cloning of the mouse apolipoprotein D gene and its upregulated expression in Niemann-Pick disease type C mouse model". DNA and Cell Biology. 15 (10): 873–82. doi:10.1089/dna.1996.15.873. PMID8892759.
^Terrisse L, Séguin D, Bertrand P, Poirier J, Milne R, Rassart E (18 June 1999). "Modulation of apolipoprotein D and apolipoprotein E expression in rat hippocampus after entorhinal cortex lesion". Brain Research. Molecular Brain Research. 70 (1): 26–35. doi:10.1016/s0169-328x(99)00123-0. PMID10381540.
^Ong WY, He Y, Suresh S, Patel SC (July 1997). "Differential expression of apolipoprotein D and apolipoprotein E in the kainic acid-lesioned rat hippocampus". Neuroscience. 79 (2): 359–67. doi:10.1016/s0306-4522(96)00608-2. PMID9200721. S2CID11857861.
Rassart E, Bedirian A, Do Carmo S, Guinard O, Sirois J, Terrisse L, et al. (October 2000). "Apolipoprotein D". Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology. 1482 (1–2): 185–98. doi:10.1016/S0167-4838(00)00162-X. PMID11058760. S2CID8189847.
Peitsch MC, Boguski MS (February 1990). "Is apolipoprotein D a mammalian bilin-binding protein?". The New Biologist. 2 (2): 197–206. PMID2083249.
Yang CY, Gu ZW, Blanco-Vaca F, Gaskell SJ, Yang M, Massey JB, et al. (October 1994). "Structure of human apolipoprotein D: locations of the intermolecular and intramolecular disulfide links". Biochemistry. 33 (41): 12451–5. doi:10.1021/bi00207a011. PMID7918467.
Holzfeind P, Merschak P, Dieplinger H, Redl B (October 1995). "The human lacrimal gland synthesizes apolipoprotein D mRNA in addition to tear prealbumin mRNA, both species encoding members of the lipocalin superfamily". Experimental Eye Research. 61 (4): 495–500. doi:10.1016/S0014-4835(05)80145-9. PMID8549691.
Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, et al. (July 1999). "Characterization of single-nucleotide polymorphisms in coding regions of human genes". Nature Genetics. 22 (3): 231–8. doi:10.1038/10290. PMID10391209. S2CID195213008.
Mahadik SP, Khan MM, Evans DR, Parikh VV (November 2002). "Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome". Schizophrenia Research. 58 (1): 55–62. doi:10.1016/S0920-9964(01)00378-4. PMID12363390. S2CID22634600.
Desai PP, Hendrie HC, Evans RM, Murrell JR, DeKosky ST, Kamboh MI (January 2003). "Genetic variation in apolipoprotein D affects the risk of Alzheimer disease in African-Americans". American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics. 116B (1): 98–101. doi:10.1002/ajmg.b.10798. PMID12497622. S2CID25171300.
Kang MK, Kameta A, Shin KH, Baluda MA, Kim HR, Park NH (July 2003). "Senescence-associated genes in normal human oral keratinocytes". Experimental Cell Research. 287 (2): 272–81. doi:10.1016/S0014-4827(03)00061-2. PMID12837283.
Thomas EA, Laws SM, Sutcliffe JG, Harper C, Dean B, McClean C, et al. (July 2003). "Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease: no relation to apolipoprotein E expression or genotype". Biological Psychiatry. 54 (2): 136–41. doi:10.1016/S0006-3223(02)01976-5. PMID12873803. S2CID46158571.
